A Phase II Study of MEDI4736 and Tremelimumab, as Monotherapy or in Combination, in Unresectable Hepatocellular Carcinoma

Full Title

A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma

Purpose

This multicenter Phase II study is evaluating the safety, antitumor activity, and immunogenicity of MEDI4736 (durvalumab) and tremelimumab given together and individually in patients with unresectable hepatocellular carcinoma. Both drugs are administered intravenously (by vein).

Eligibility

This study is for patients who:

  • Have unresectable hepatocellular carcinoma.
  • Have not previously received immunotherapy.
  • Are age 18 or older.

For more information and to inquire about eligibility for this study, please contact Dr. Ghassan Abou-Alfa at 646-888-4184.

Protocol

16-063

Phase

I/II

Investigator

Co-Investigators

Locations